CEO Fired
iGate sacks CEO Phaneesh Murthy
Outsourcing company iGate Corp said it had sacked its Chief Executive Phaneesh Murthy for not disclosing a relationship with a subordinate after investigating one of India's best-known IT executives for sexual harassment. Full Article
REUTERS SHOWCASE
Buy, Sell or Hold?
Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade. Full Coverage
Reuters India Mobile
Get the latest news on the go. Visit Reuters India on your mobile device. Full Coverage
Glenmark gains on USFDA nod for diarrhoea drug
Track Markets: BSE Sectoral Indices
Track and analyse performance of all BSE sectoral indices and other global indices on a single page. Full Coverage
Reuters Market Eye - Shares in Glenmark Pharmaceuticals (GLEN.NS) gain 2.5 percent after U.S. health regulators approved Salix Pharmaceuticals Ltd's (SLXP.O) drug to treat diarrhoea in HIV/AIDS patients on qantiretroviral therapy, a combination of medicines used to treat HIV infection.
Glenmark will be the active pharmaceutical ingredients supplier for the drug to Salix in regulated markets.
An international arbitrator ruled in August 2012 that Glenmark Pharmaceuticals has the right to sell its HIV-associated diarrhoea drug Crofelemer in 140 countries.
Edelweiss in a report says, "The overall potential market for Crofelemer is anticipated at $300 million-$500 million and peak potential revenue for Glenmark, from API supply, could be $15 million-$20 million per annum."
(Reporting by Abhishek Vishnoi)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters